Business Development as a Strategic Lever: Looking at how Biopharma Companies are tapping into a mix of Acquisitions, Licensing, and Partnerships to Reposition for Growth

From biosimilars scale to targeted oncology innovation, recent deals highlight how companies are using acquisition to accelerate positioning across key therapeutic and market opportunities.

In Part 4 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On what late-stage setbacks and tolerability trade-offs reveal about portfolio planning and platform expansion.

In Part 3 of our Series on how the pharma landscape is being reshaped - from the inside out - we have Eyes On where late-stage clinical execution is still cutting through uncertainty as de-risked assets redefine standards of care and company trajectories.

In Part 2 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how policy and regulation are redefining pricing, access, and market stability.

In Part 1 of our Series on how the pharma landscape is being reshaped - from the inside out, we have Eyes On how cost discipline, manufacturing shifts, and portfolio resets are reshaping large pharma.

MFN — once a policy abstraction — is now reshaping corporate strategy, pricing frameworks, and commercialization models.